TMS may be worth discussing with a prescriber if you have major depressive disorder and an antidepressant trial has not helped adequately; that is the population described in the original NeuroStar FDA clearance. Whether it is right for you requires a consultation that checks your diagnosis, treatment history, safety considerations, and the proposed device’s current labeling—not a self-assessment score.
This guide helps you prepare for that conversation. It cannot establish eligibility or tell you which treatment to choose.
Start with the condition being treated
Transcranial magnetic stimulation, or TMS, uses magnetic pulses delivered through a coil near the scalp to stimulate targeted brain areas. Before discussing a treatment schedule, ask the prescriber what diagnosis and symptoms they intend to treat.
The original NeuroStar clearance covers adults with major depressive disorder who did not achieve satisfactory improvement after an adequate antidepressant trial. That is a specific device indication, not blanket clearance for every condition associated with low mood.
Device labeling can differ. The original clearance cited here is not a complete catalog of current TMS indications. Ask the clinic to identify its device and explain whether your diagnosis, age, and proposed treatment fall within that device’s current FDA-cleared labeling.
If the proposed use falls outside its cleared labeling, it is off-label. Off-label use is not the same as FDA clearance; the prescriber should explain the rationale, evidence, uncertainties, alternatives, and coverage implications. A clinic offering a treatment does not itself establish FDA clearance.
You can explore our condition-specific TMS information to prepare questions, but confirm the regulatory status of your proposed treatment during the consultation.
What does “treatment-resistant” mean?
Treatment resistance describes an inadequate response to treatment; it is not a judgment about your effort or motivation. The term alone does not establish TMS eligibility.
In clinical practice, a prescriber reviews which medications you tried, whether the doses and durations were adequate, how consistently you could take them, and what happened. A medication stopped early because of side effects tells a different story from an adequately completed trial that brought little improvement. Both experiences matter, but they may be documented differently.
Clinicians also consider psychotherapy, the accuracy of the diagnosis, ongoing stressors, substance use, and medical problems that could affect symptoms. A partial response deserves documentation too: improved sleep with persistent hopelessness is different from no change at all.
Keep these distinctions in mind:
- FDA-cleared indication: The original NeuroStar clearance specified failure of one adequate antidepressant trial.
- Clinical suitability: The prescriber evaluates your broader circumstances and whether the proposed treatment makes sense for you.
- Insurance eligibility: Your plan may apply its own documentation and authorization requirements.
Ask the clinic how it defines an adequate trial and treatment resistance. Do not assume that a phrase in a referral letter automatically satisfies a device’s labeling or your insurer’s policy.
Questions to ask yourself before booking
You do not need perfect records or certainty about your diagnosis to seek a consultation. These questions can help make the visit more useful:
- What symptoms most interfere with my daily life?
- What diagnosis has my treating clinician documented?
- Which treatments helped, even partly, and which caused problems?
- Have I had periods of unusually elevated mood, reduced need for sleep, or marked impulsivity?
- Are alcohol, other substances, sleep problems, or medical conditions complicating the picture?
- What would meaningful improvement look like to me?
- Can I realistically attend the schedule the clinic proposes?
Share uncertainty rather than trying to answer in a way that makes you appear eligible. The goal is an accurate assessment, not passing a test.
What to bring to a consultation
A concise treatment summary can be more useful than trying to recall everything during the appointment. Bring what you have; missing records can often be requested later.
Your treatment history
- Medication names, doses, approximate dates, and reasons for stopping.
- Benefits and side effects, including partial or short-lived improvement.
- Psychotherapy history and other psychiatric treatments.
- Relevant psychiatric assessments, hospital discharge summaries, or referral notes.
Your current health information
- All prescription medicines, nonprescription products, and supplements.
- Seizure history, significant head injuries, and neurological conditions.
- Implanted devices, metal in or near the head, and any available device identification cards.
- Current sleep patterns, substance use, and recent medication changes.
These details support screening rather than automatically excluding you. The TMS safety guidelines emphasize evaluation of patient factors, stimulation parameters, and device-related risks. Do not stop or change medication on your own to qualify.
Your goals and practical questions
Bring your insurance information, referring clinician’s contact details, and a description of the daily activities you hope to regain. Ask who will prescribe treatment, who will administer it, and how your existing clinician will receive updates.
Safety deserves a separate conversation
Ask the prescriber to explain common discomforts, important risks, and what would prompt a pause or reassessment. A reassuring discussion should still acknowledge uncertainty.
Seizure is the most serious potential adverse effect; its risk is low with standard stimulation parameters and focal coils, according to the expert safety guidelines. Low risk does not mean no risk, and a general statement cannot replace your individual screening.
Implanted electronic devices or metal near the treatment area require specific evaluation. A history of seizures also warrants individualized assessment rather than a promise of safety or an automatic conclusion from an online checklist. Discuss these issues before treatment begins, consistent with the safety recommendations.
When another option may deserve attention first
An honest consultation can end with further assessment or a different plan—not necessarily TMS.
Your diagnosis needs clarification. A history suggesting mania, psychosis, substance-related symptoms, or a contributing medical condition may change the treatment discussion. If TMS is still proposed, ask whether that particular use is FDA-cleared for the device or off-label.
Your earlier treatment was not adequately assessed. Missing records, uncertain dosing, or difficulty taking medication consistently can make “treatment failure” hard to interpret. A prescriber may need to clarify those issues before comparing options.
Your situation requires urgent care. If you may act on suicidal thoughts or cannot keep yourself safe, seek immediate emergency evaluation rather than waiting for a routine TMS consultation. A scheduled outpatient assessment is not a crisis service.
Safety questions remain unresolved. Device compatibility, neurological history, or changing health circumstances may require additional review.
The practical burden is not manageable. Travel, work, caregiving, and coverage constraints are legitimate considerations. They should shape a realistic discussion, not be treated as lack of commitment.
None of these points determines your treatment by itself. They are reasons for a prescriber to compare options carefully with you.
Keep expectations realistic
TMS can help some patients, but improvement is not guaranteed. A multisite observational study of depression treatment reported clinical response in 58.0% and remission in 37.1% of 307 outpatients. These group results do not predict your individual outcome, and an observational study is not a randomized comparison.
Benefit also does not necessarily eliminate future treatment needs. In a follow-up study of durability, some patients needed TMS reintroduction. Ask how the clinic measures progress, decides whether to continue, and plans care after the initial course.
Plan a workable New Jersey consultation
When comparing New Jersey TMS providers, consider the actual trip as well as the consultation itself. If you live in Princeton or commute through Jersey City, ask how the proposed schedule fits your travel and work commitments.
Review our TMS insurance guidance, then confirm authorization requirements and your expected financial responsibility with the clinic and insurer. Clinical suitability and coverage are separate questions.
Leave the consultation knowing the proposed diagnosis, whether treatment is FDA-cleared or off-label, unresolved safety questions, alternatives, and next steps. You do not need to decide before those points are clear.
References
- Carpenter LL et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depression and Anxiety, 2012. PMID 22689344
- US FDA 510(k) clearance K083538 (NeuroStar TMS System), 2008
- Rossi S et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert guidelines. Clinical Neurophysiology, 2021. PMID 33243615
- Dunner DL et al. A multisite, naturalistic, observational study of TMS for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry, 2014. PMID 25271871